Hoth Therapeutics, Inc. (HOTH) Stock price, Description, News & Info

#Thinksabio latest news

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities